Description du projet
Une nouvelle radiothéranostique multifonctionnelle basée sur des complexes supramoléculaires
La radiothéranostique est un domaine émergent de la médecine nucléaire qui permet l’imagerie et la thérapie simultanées en émettant un rayonnement ciblé sur les noyaux cellulaires afin d’induire la mort cellulaire. Elle s’appuie généralement sur des produits radiopharmaceutiques injectables sous forme de molécules uniques qui incorporent un radio-isotope thérapeutique ou diagnostique. Le projet SMARTdrugs, financé par le CEI, entend exploiter l’extraordinaire potentiel de la chimie supramoléculaire pour développer une nouvelle classe de médicaments radiothéranostiques multifonctionnels. L’équipe se propose de créer ces médicaments radiothéranostiques supramoléculaires par auto-assemblage de complexes de coordination supramoléculaires hôte-invité et à l’aide de molécules moléculairement imbriquées comme échafaudages. Ils cibleront dans un premier temps les cancers, mais les résultats seront pertinents pour d’autres applications d’administration de médicaments et utiles pour la recherche fondamentale sur les interactions biologiques.
Objectif
From diagnostic applications in the quantification and characterisation of biomarker expression in cancer patients, through to molecularly targeted radionuclide therapy, radiopharmaceuticals are at the frontline of modern personalised medicine. The radical long-term vision of SMARTdrugs is to harness the untapped potential of supramolecular chemistry to create a new class of therapies - radiotheranostics - which combine both diagnostic and therapeutic radionuclides in one compound. By using the self-assembly of host-guest supramolecular coordination complexes and molecularly interlocked molecules as scaffolds for creating supramolecular radiotheranostic drugs, new methods for radiotheranostic synthesis that break away from conventional medicinal chemistry concept will be introduced. SMARTdrugs will establish a proof-of-concept demonstrating the utility of non-covalent systems in the design of multifunctional radiotheranostic agents with tailored pharmacokinetics, and their application in challenging drug-delivery scenarios including targeted delivery to cancers of the lung and brain.
Our 3 main objectives:
Objective 1 – Develop new chemical landscapes using non-covalent bonding to create functionalised supramolecular compounds for cancer-specific theranostics
Objective 2 – Elucidate the key relationships between supramolecular radiotheranostics and the complex tumour microenvironment that determine drug efficacy in vivo
Objective 3 – Perform head-to-head studies to establish a proof-of-principle that supramolecular chemistry is a viable alternative to classical radiopharmaceutical design
The long-term goal is to establish a new chemical landscape for radiotheranostic design, and to facilitate clinical translation of this new technology. Successful experiments will lay the foundations for exploiting supramolecular chemistry in the wider context of drug delivery and theranostics, and for studying biological interactions at the cellular to whole-organism levels.
Champ scientifique
- medical and health sciencesbasic medicinemedicinal chemistry
- natural scienceschemical sciencesnuclear chemistryradiochemistry
- medical and health sciencesclinical medicineoncology
- medical and health scienceshealth sciencespersonalized medicine
- natural sciencesbiological sciencesbiological behavioural sciencesethologybiological interactions
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Régime de financement
HORIZON-EIC - HORIZON EIC GrantsCoordinateur
80333 Muenchen
Allemagne